Tachyphylaxis

Tachyphylaxis is the rapid decrease in response to a drug after repeated administration over a short period. The term derives from Greek: tachy (rapid) + phylaxis (protection). Unlike tolerance (which develops over days to weeks), tachyphylaxis can occur within hours or even after a single dose.

Mechanism

Most peptide receptors are G-protein-coupled receptors (GPCRs). After agonist binding and signal transduction, GPCRs undergo a desensitization cascade:

1. Phosphorylation — G-protein-coupled receptor kinases (GRKs) phosphorylate the agonist-occupied receptor's intracellular domains
2. Beta-arrestin recruitment — beta-arrestins bind the phosphorylated receptor, physically blocking G-protein coupling and terminating signaling
3. Internalization — the receptor-arrestin complex is endocytosed via clathrin-coated pits, removing the receptor from the cell surface
4. Recycling or degradation — internalized receptors are either dephosphorylated and recycled to the surface (resensitization) or routed to lysosomes for degradation (downregulation)

Steps 1–2 occur within minutes. Step 3 takes minutes to hours. Step 4 determines whether the receptor population recovers quickly or requires new receptor synthesis.

Tachyphylaxis vs. tolerance vs. desensitization

• Tachyphylaxis: Rapid loss of response, often after one or very few doses. Primarily receptor-level
• Desensitization: Specific term for the receptor-level phosphorylation/arrestin/internalization process. A mechanism that produces tachyphylaxis
• Tolerance: Broader term encompassing slower adaptive changes — receptor downregulation, downstream pathway adaptation, metabolic tolerance. Develops over days to weeks

In practice, these terms overlap. A GHRP-6 user observing a blunted GH response on the second daily injection is experiencing tachyphylaxis from receptor desensitization. The same user noticing reduced effects after 8 weeks is experiencing tolerance from receptor downregulation and somatostatin adaptation.

Peptides most affected by tachyphylaxis

High tachyphylaxis:

• GHRP-2, GHRP-6, hexarelin — the GH response to a second daily dose is typically 30–50% of the first dose
• Continuous GnRH — rapid and complete GnRH receptor desensitization within days (therapeutically exploited in cancer treatment)

Moderate tachyphylaxis:

• Melanotan II / PT-141 — MC4R-mediated sexual arousal effects diminish with frequent dosing
• CJC-1295 DAC — continuous GHRH receptor exposure from long half-life may accelerate desensitization

Low tachyphylaxis:

• Ipamorelin — most selective GHSR agonist with less desensitization than other GHRPs
• Semaglutide — GLP-1 receptor shows minimal clinical tachyphylaxis at therapeutic doses
• BPC-157 — mechanism does not involve a single GPCR target in the classical sense

Clinical significance for peptide protocols

Tachyphylaxis is the pharmacological basis for several peptide protocol recommendations:

• GHS dosing frequency: Maximum 2–3 daily injections spaced >3 hours apart. Third doses produce minimal additional GH release
• Peptide cycling: Off-periods allow receptor recycling and resensitization. Typical cycles: 8–12 weeks on, 4–6 weeks off
• Pulsatile vs. continuous delivery: Pulsatile patterns (mimicking endogenous hormone release) produce less desensitization than continuous exposure for most peptide receptors
• Dose escalation awareness: If you're increasing doses to maintain the same effect, tachyphylaxis is likely occurring. The solution is a break, not a higher dose